Victory Capital Management Inc. Sells 12,888 Shares of Harvard Bioscience, Inc. (NASDAQ:HBIO)

Victory Capital Management Inc. cut its holdings in shares of Harvard Bioscience, Inc. (NASDAQ:HBIO) by 49.6% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 13,112 shares of the medical instruments supplier’s stock after selling 12,888 shares during the period. Victory Capital Management Inc.’s holdings in Harvard Bioscience were worth $109,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also recently modified their holdings of HBIO. Sowell Financial Services LLC increased its position in shares of Harvard Bioscience by 28.8% in the first quarter. Sowell Financial Services LLC now owns 12,039 shares of the medical instruments supplier’s stock valued at $88,000 after acquiring an additional 2,693 shares during the last quarter. Citadel Advisors LLC acquired a new stake in shares of Harvard Bioscience in the first quarter valued at about $71,000. Trexquant Investment LP acquired a new stake in shares of Harvard Bioscience in the first quarter valued at about $76,000. Jane Street Group LLC acquired a new stake in shares of Harvard Bioscience in the first quarter valued at about $81,000. Finally, BNP Paribas Arbitrage SA increased its position in Harvard Bioscience by 70.0% during the first quarter. BNP Paribas Arbitrage SA now owns 17,964 shares of the medical instruments supplier’s stock worth $98,000 after buying an additional 7,394 shares during the last quarter. Institutional investors own 68.41% of the company’s stock.

Shares of HBIO stock opened at $7.60 on Tuesday. The company has a current ratio of 2.30, a quick ratio of 1.24 and a debt-to-equity ratio of 0.52. The stock has a market cap of $309.80 million, a P/E ratio of -95.00 and a beta of 1.75. The stock has a 50 day simple moving average of $8.01 and a 200 day simple moving average of $7.27. Harvard Bioscience, Inc. has a 1 year low of $2.74 and a 1 year high of $8.75.

Separately, Zacks Investment Research downgraded Harvard Bioscience from a “hold” rating to a “sell” rating in a research report on Tuesday, August 17th.

About Harvard Bioscience

Harvard Bioscience, Inc develops, manufactures, and sells technologies, products and services that enable fundamental research, discovery, and pre-clinical testing for drug development. It operates under the geographical segments: United States, Germany, United Kingdom, and Rest of the world. It sells its products through catalog, Website, distributors, and direct sales force.

Recommended Story: Is it Safe to Invest in Commodities?

Institutional Ownership by Quarter for Harvard Bioscience (NASDAQ:HBIO)

Receive News & Ratings for Harvard Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harvard Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.